Evidence map›Paper›PMID 28281085›Full record

ArticleIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2017

Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis.

Narendra S Choudhary, Amit Kumar, Vijay Bodh, Shyam Bihari Bansal, Reetesh Sharma, Manish Jain, Sanjiv Saigal, Neeraj Saraf

Abstract read
PubMed Publisher
In one paragraph

Article in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Outcome of hepatitis C-related liver transplantation in direct-acting antiviral era.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2020
    Article
  5. Article
  6. Article
  7. Observational
  8. Preliminary experience with sofosbuvir-based treatment regimens for patients dependent on hemodialysis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2018
    Article
  9. Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs?Journal of clinical and experimental hepatology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Narendra S ChoudharyMedanta Liver Institute, Medanta The Medicity, Gurgaon, Haryana, 122 018, India.
Amit KumarMedanta Liver Institute, Medanta The Medicity, Gurgaon, Haryana, 122 018, India.
Vijay BodhMedanta Liver Institute, Medanta The Medicity, Gurgaon, Haryana, 122 018, India.
Shyam Bihari BansalMedanta Kidney Institute, Medanta The Medicity, Gurgaon, Haryana, 122 018, India.
Reetesh SharmaMedanta Kidney Institute, Medanta The Medicity, Gurgaon, Haryana, 122 018, India.
Manish JainMedanta Kidney Institute, Medanta The Medicity, Gurgaon, Haryana, 122 018, India.
Sanjiv SaigalMedanta Liver Institute, Medanta The Medicity, Gurgaon, Haryana, 122 018, India.
Neeraj SarafMedanta Liver Institute, Medanta The Medicity, Gurgaon, Haryana, 122 018, India. neerajsaraf@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatients with end-stage renal disease (ESRD) have poor treatment tolerance and outcome to interferon-based regimens. Sofosbuvir-based regimens have improved treatment success in chronic hepatitis C. There is limited data in ESRD patients as sofosbuvir is excreted by the kidney. Several small studies have shown good results.

methodsSixteen consecutive patients of ESRD (on dialysis) and chronic hepatitis C were treated with sofosbuvir-based regimens as they were prospective kidney transplantation recipients, at a tertiary care center in north India. Sofosbuvir was given 400 mg on alternate days. Data is shown as number, mean (SD), and median (range).

resultsSixteen patients (12 males) aged 45±12 years received sofosbuvir-based treatment. These patients were on hemodialysis from 10 (2-48) months. Eleven of these patients had genotype 1, four had genotype 3, and one had genotype 4 infection; baseline RNA was 7 (5-8) log. The following treatment regimens were used: sofosbuvir, ribavirin, and low dose peginterferon (n = 8; 6 genotype 1 and one each had genotype 3 and 4); sofosbuvir and daclatasvir (n = 7); sofosbuvir, ribavirin, and daclatasvir (n = 1). Ten patients achieved end of treatment response and 8 (80%) of these achieved sustained virological response at 12 weeks (SVR12); six are on treatment. Two patients with genotype one (including one with cirrhosis) had relapse. Seven patients needed blood transfusion; interferon was stopped in one due to thrombocytopenia. Fatigue was present in 4 patients.

conclusionSofosbuvir-based regimens can be used in ESRD patients on dialysis with good efficacy.

Indexed as

AdultAntiviral AgentsDrug Administration ScheduleDrug Therapy, CombinationFemaleGenotypeHepacivirusHepatitis C, ChronicHumansKidney Failure, ChronicMaleMiddle AgedRenal DialysisSofosbuvirTreatment OutcomeAntiviral AgentsSofosbuvirChronic kidney diseaseDaclatasvirDialysisSofosbuvirSustained viral response

Identifiers

PMID28281085

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.